Myrbetriq Side Effects: Blood Pressure, Dementia & Safety

Myrbetriq (mirabegron) is generally well tolerated compared with older overactive bladder drugs, but it does carry a distinct set of side effects that you should understand before starting or continuing therapy. The most commonly reported issues involve mild increases in blood pressure, urinary tract infections, headache, and nasal congestion. What sets Myrbetriq apart from the older anticholinergic bladder medications is what it largely avoids: dry mouth, constipation, and cognitive fog. Still, its side-effect profile is more nuanced than a simple list of common complaints, especially when cardiovascular health, drug interactions, or long-term use enter the picture.

How Myrbetriq Works and Why Its Side Effects Differ

Myrbetriq relaxes the bladder muscle through a completely different pathway than the anticholinergic drugs (like oxybutynin or solifenacin) that have been used for decades. Instead of blocking acetylcholine receptors throughout the body, it activates beta-3 adrenergic receptors concentrated in the bladder wall. In a normal bladder, this quiets certain nerve fibers that signal urgency; in pathological conditions it can also reduce involuntary muscle contractions by dampening the release of acetylcholine at the nerve-muscle junction itself.¹ Because it is not blocking acetylcholine receptors in the gut, the salivary glands, or the brain, you largely escape the side effects those drugs are notorious for. The trade-off is that beta-3 receptors also exist in blood vessels and fat tissue, so the side effects Myrbetriq does cause tend to show up in different places.

Blood Pressure and Heart Rate

The cardiovascular signal is the side effect most worth paying attention to. At the standard 25 mg or 50 mg dose, the average bump in blood pressure is modest. In a study of over 260 patients with overactive bladder, average systolic blood pressure did not change in a statistically meaningful way after mirabegron treatment. However, roughly one in five patients in the overall group did experience a rise in systolic blood pressure of 10 mmHg or more, with older adults more prone to this bump than younger ones.² Pulse rate did not change significantly in that study.

The dose matters a great deal. A study in healthy volunteers tested mirabegron at 50 mg, 150 mg, and 200 mg (the latter two well above the prescribed ceiling) and found that blood pressure and heart rate climbed sharply at higher doses. After a 200 mg dose, systolic blood pressure rose by about 9 mmHg on average and heart rate increased by about 9 beats per minute, compared with roughly 2 mmHg and 3 beats per minute at the 50 mg dose.³ The practical takeaway is that sticking to your prescribed dose is more important with Myrbetriq than with many other medications, and if your blood pressure is already poorly controlled, your doctor will want to monitor you more closely.

In long-term Japanese studies running 52 weeks, the changes in blood pressure and pulse rate over time were not considered clinically significant at standard doses.⁴ So while the cardiovascular effect is real, it tends to be small and stable rather than progressive.

Dry Mouth and Constipation Are Largely Absent

If you have switched to Myrbetriq from an anticholinergic bladder drug, you probably already know the main reason people make that switch. Dry mouth, one of the most common complaints with drugs like oxybutynin and solifenacin, occurs at roughly the same rate with mirabegron 50 mg as with a placebo. A large network meta-analysis of 54 studies covering over 40,000 patients found that the odds of dry mouth with mirabegron were similar to placebo and significantly lower than with every other active anticholinergic treatment tested.⁵ A separate systematic review reached the same conclusion.⁶

Constipation follows the same pattern. The same network meta-analysis found the risk of constipation with mirabegron 50 mg to be similar to placebo and significantly lower than with nine anticholinergic treatments.⁷ For many people, especially older adults already struggling with regularity, this is the deciding advantage.

Cognitive Effects and Dementia Risk

One of the most serious concerns with the older anticholinergic bladder drugs is their potential to impair memory and increase the long-term risk of dementia, especially in older adults. Myrbetriq does not block acetylcholine receptors in the brain, and the data reflect that difference. In the PILLAR trial, a phase 4 study specifically designed to measure cognitive effects in elderly patients, mirabegron showed no statistically significant change in cognitive function scores compared with placebo over the treatment period.⁸

A large population-based cohort study compared patients with overactive bladder treated with anticholinergics against those treated with a beta-3 agonist like mirabegron. Anticholinergic users had a roughly 23% higher risk of developing new-onset dementia compared with the beta-3 agonist group.⁹ This does not prove that anticholinergics cause dementia or that Myrbetriq protects against it, but the gap is consistent enough that many geriatricians now prefer Myrbetriq for older patients specifically because of the cognitive safety profile.

Drug Interactions Worth Knowing About

Myrbetriq inhibits an enzyme in the liver called CYP2D6, which is responsible for breaking down a surprisingly long list of common medications. In pharmacokinetic studies, mirabegron at higher doses roughly tripled the blood levels of metoprolol (a common blood-pressure medication) and the antidepressant desipramine.¹⁰ At the labeled doses, the effect is classified as moderate CYP2D6 inhibition, but “moderate” still means that drugs processed by this enzyme can hang around in your blood longer and at higher concentrations than expected.

What does this mean practically? If you take metoprolol, certain antidepressants (like desipramine, fluoxetine, or paroxetine), codeine, tamoxifen, or other drugs metabolized by CYP2D6, your prescriber should know you are on Myrbetriq. In some cases the dose of the other drug needs to be reduced. The interaction with metoprolol is worth special attention because both drugs can affect blood pressure, and a doubled or tripled metoprolol level could cause symptoms like dizziness, fatigue, or an abnormally slow heart rate.

When Myrbetriq Is Combined with Solifenacin

Some people end up on combination therapy, taking Myrbetriq alongside solifenacin (an anticholinergic) when neither drug alone controls their symptoms. This combination is available as a single tablet in some markets. The side-effect profile of the combination is largely predictable: you get a bit more of the anticholinergic side effects like dry mouth and constipation, since solifenacin brings those along. In the SYNERGY II trial, about 49% of patients in the combination group experienced at least one side effect versus 41% on mirabegron alone. Dry mouth and constipation were both more common in the combination group, as expected. Urinary tract infections were also slightly more frequent with the combination (about 8% versus 6% for either drug alone).¹¹ An earlier phase 2 trial similarly found a slight uptick in constipation with the combination but no dose-related trends in blood pressure, pulse rate, or heart rhythm changes.¹²

Tachyarrhythmias (abnormal fast heart rhythms) were reported at similar rates in the combination and mirabegron-alone groups (about 3%) and were slightly higher than in the solifenacin-alone group (1%).¹³ These were mostly mild, but if you already have a history of arrhythmias, the combination warrants more careful monitoring.

Rare Allergic and Skin Reactions

Serious allergic reactions to Myrbetriq are uncommon but documented. The FDA lists mirabegron as a potential cause of several skin conditions including hives, itching, angioedema (sudden deep tissue swelling, often of the face or throat), leukocytoclastic vasculitis, and purpura.¹⁴ In one published case, a 77-year-old woman developed tongue angioedema after being on mirabegron consistently for three to four years, a reminder that allergic reactions can emerge long after starting a drug.¹⁵ Any unexplained swelling of the lips, tongue, or throat while on Myrbetriq is a reason to seek immediate medical attention and stop the drug.

Long-Term Safety Over Months and Years

One of the legitimate anxieties with any drug taken daily for a chronic condition is whether side effects accumulate or new problems appear after months or years. A three-year Japanese post-marketing surveillance study of over 1,100 patients found that the incidence of adverse drug reactions actually decreased over time. In the first year, adverse reactions occurred at a rate of about 1 to 2% per quarter; by the second and third years, rates dropped below 1% per quarter. No cumulative or delayed-onset specific reactions were observed.¹⁶ In a real-world multicenter study, about 54% of patients were still on mirabegron at 10 to 12 months, which is fairly good persistence for a bladder medication and suggests that most people find the side effects manageable enough to continue treatment.¹⁷

People with Kidney or Liver Problems

If your kidneys or liver are not working well, mirabegron levels in your blood can climb substantially. In people with severe kidney impairment, total drug exposure roughly doubled compared with healthy volunteers. In those with moderate liver impairment, the peak drug concentration nearly tripled.¹⁸ Higher blood levels mean a higher chance of side effects, especially the cardiovascular ones. This is why the prescribing information recommends a lower dose for patients with moderate kidney or liver disease and advises against using Myrbetriq at all in people with severe liver impairment.

Children and Adolescents

Myrbetriq has been studied in pediatric patients with neurogenic detrusor overactivity, a condition often related to spina bifida or spinal cord problems. In an open-label phase 3 dose-titration study, mirabegron was well tolerated in children and adolescents with a side-effect profile that aligned with what is seen in adults.¹⁹ Both tablet and oral suspension formulations were well tolerated, though some children found the taste of the suspension unpleasant.²⁰ Pediatric dosing is weight-based rather than the flat adult doses, so your child’s prescriber will calculate the appropriate amount.

Eyes and Glaucoma

Anticholinergic bladder drugs can raise intraocular pressure and are generally avoided in people with narrow-angle glaucoma. Myrbetriq works through a different mechanism, and a small study specifically measured intraocular pressure in patients with glaucoma before and during mirabegron treatment. There was no significant change in eye pressure at either 4 or 12 weeks of treatment.²¹ While this is reassuring, the study was small, so if you have glaucoma your ophthalmologist should still be aware of any new medications you start.

An Unexpected Metabolic Upside

Beta-3 receptors are not only in the bladder. They are also found on brown fat and beige fat, the metabolically active fat tissue that burns calories to produce heat. Researchers noticed that mirabegron, by activating these receptors, increased whole-body oxygen consumption and glucose uptake into fat tissue in animal models, effects that improved glucose tolerance.²²

More striking are the human data. A clinical trial in obese, insulin-resistant adults found that mirabegron treatment improved oral glucose tolerance, reduced hemoglobin A1c (a marker of long-term blood sugar control), and improved both insulin sensitivity and beta cell function.²³ This does not mean Myrbetriq should be used as a diabetes treatment. The doses explored in metabolic research are sometimes higher than the bladder dose, and no regulatory body has approved it for this purpose. But if you happen to be taking Myrbetriq for your bladder and also have insulin resistance or prediabetes, this metabolic nudge is a side effect running in your favor rather than against you. It is a line of research still in its early stages.

What to Do in Case of Overdose

There is no specific antidote for mirabegron overdose. If someone takes substantially more than prescribed, the primary concern is cardiovascular: elevated blood pressure and increased heart rate proportional to the dose. Management is supportive, focused on cardiac monitoring and treating symptoms as they arise. At doses well above the therapeutic range (150 mg and 200 mg), healthy volunteers showed blood pressure rises of 7 to 9 mmHg and heart rate increases of up to 9 bpm, which are uncomfortable but were not life-threatening in a controlled setting.²⁴ Still, anyone who suspects an overdose should contact a poison control center or emergency services, especially if they already have heart disease or uncontrolled hypertension.

Real-World Pharmacovigilance Signals

Beyond controlled trials, post-market surveillance through the FDA’s Adverse Event Reporting System (FAERS) gives a broader picture of what happens when millions of real patients take a drug. A recent analysis of FAERS data for mirabegron examined the real-world safety profile and looked for unexpected signals.²⁵ The FAERS database is useful for flagging rare events that clinical trials might miss, but it has important limitations: anyone can submit a report, so the data are unverified and cannot establish causation. The events reported most often in this system align with what clinical trials have shown: urinary tract infections, hypertension, headache, and urinary retention. Occasionally, reports of atrial fibrillation surface in pharmacovigilance, which is consistent with the known cardiovascular mechanism but occurs at low enough rates that it did not emerge as a major signal in controlled trials.

The important distinction with FAERS reports is that a reported event is not necessarily caused by the drug. If a million people over age 65 take any medication, some will develop atrial fibrillation during the treatment period simply because they are in a population where that happens. Pharmacovigilance data are useful for generating hypotheses and triggering further investigation, not for drawing firm conclusions about causation.